Clinical Trials for Mesothelioma Patients: Bortezomib Projected Outcomes Criteria

Read the projected outcomes criteria about a current clinical trial being conducted to study the effects of Bortezomib for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the clinical trials are not being conducted in the United States.

Projected Accrual:

57 first-line setting and 54 second-line setting patients will be accrued for this study.

Primary Outcome Measures:
• Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria

Secondary Outcome Measures: • Time to disease progression • Overall survival • Safety • Quality of life

Recruitment Information:
Recruitment Status: Recruiting
Enrollment: 111
Start Date: September 2006

Courtesy of ClinicalTrials.gov,

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney